TRIM-edicine is a biotechnology company developing novel biopharmaceutical products for the treatment of several important unmet medical needs, including cancer, oral healthcare, dermal wounds, ischemia/reperfusion injury, sports medicine and muscular dystrophy. The company is built around a core of protein therapeutic approaches that involve novel proteins targeting a variety of cellular pathways that are altered in numerous disease states. R&D efforts at TRIM-edicine focus on providing proof-of-concept support to validate the technology and facilitate partnerships with various established companies in the biomedical field. With ties to Rutgers and Ohio State, TRIM-edicine has obtained global patent protection on the MG53 protein for tissue repair, including composition and utility applications.
